糖尿病患者足部感染与肾损伤关联的回顾性队列研究

注册号:

Registration number:

ChiCTR2400089187 

最近更新日期:

Date of Last Refreshed on:

2024-09-03 15:25:19 

注册时间:

Date of Registration:

2024-09-03 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

糖尿病患者足部感染与肾损伤关联的回顾性队列研究

Public title:

Retrospective cohort study of kidney injury from foot infection in diabetic patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

探索糖尿病患者足部感染与肾脏损伤的关联 — 一项基于真实世界数据回顾性队列研究

Scientific title:

Exploring the Association between Foot Infections in Diabetic Patients and Kidney Damage - A Retrospective Cohort Study Based on Real-World Data

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

彭洁 

研究负责人:

彭洁 

Applicant:

peng jie 

Study leader:

peng jie 

申请注册联系人电话:

Applicant telephone:

+86 188 1075 3264

研究负责人电话:

Study leader's
telephone:

+86 188 1075 3264

申请注册联系人传真 :

Applicant Fax:

+86 02081332723

研究负责人传真:

Study leader's fax:

+86 02081332723

申请注册联系人电子邮件:

Applicant E-mail:

1447978423@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1447978423@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广州市越秀区沿江西路104号

研究负责人通讯地址:

广州市越秀区沿江西路104号

Applicant address:

104 Yanjiang West Road, Yuexiu District, Guangzhou

Study leader's address:

104 Yanjiang West Road, Yuexiu District, Guangzhou

申请注册联系人邮政编码:

Applicant postcode:

510120

研究负责人邮政编码:

Study leader's postcode:

510120

申请人所在单位:

中山大学孙逸仙纪念医院

Applicant's institution:

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

研究负责人所在单位:

中山大学孙逸仙纪念医院

Affiliation of the Leader:

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SYSKY-2024-345-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学孙逸仙纪念医院医学伦理委员会

Name of the ethic committee:

Sun Yat-sen Memorial Hospital of Sun Yat-sen University Medical Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2024-05-08 00:00:00

伦理委员会联系人:

区柳珊

Contact Name of the ethic committee:

Qu LiuShan

伦理委员会联系地址:

广州市越秀区沿江西路104

Contact Address of the ethic committee:

104 Yanjiang West Road, Yuexiu District, Guangzhou City

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 188 1075 3264

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1447978423@qq.com

研究实施负责(组长)单位:

中山大学孙逸仙纪念医院

Primary sponsor:

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

研究实施负责(组长)单位地址:

广州市越秀区沿江西路104号

Primary sponsor's address:

104 Yanjiang West Road, Yuexiu District, Guangzhou

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong province

City:

Guangzhou city

单位(医院):

中山大学孙逸仙纪念医

具体地址:

广州市越秀区沿江西路104

Institution
hospital:

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Address:

104 Yanjiang West Road, Yuexiu District, Guangzhou

经费或物资来源:

Source(s) of funding:

none

研究疾病:

糖尿病足溃疡  

Target disease:

diabetic foot ulcer

研究疾病代码:

BD54

Target disease code:

BD54

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

探索糖尿病患者足部感染与肾功能损伤的关联,探索糖尿病足部感染患者发生肾损伤的可能危险因素。  

Objectives of Study:

To explore the association between foot infection and renal function injury in diabetic patients, and to explore the possible risk factors of kidney injury in diabetic foot infection patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1)使用免疫抑制剂、化疗药物、放疗或全身性皮质类固醇治疗患者; 2)合并有肿瘤及放化疗史(血液系统恶性肿瘤、骨髓瘤性肾病、溶血尿毒综合征、淋巴瘤、白血病、免疫球蛋白沉积性肾病); 3)CD4<200/mm3的HIV患者; 4)泌尿系统梗阻性疾病史或可能导致梗阻的情况; 5)肾小球肾炎、间质性肾炎、肾脏淀粉样变性、多囊肾慢性肾衰竭、入院前1周使用经肾脏代谢或肾毒性药物; 6)风湿免疫性疾病(如狼疮); 7)随访数据缺失。

Exclusion criteria:

1) Treatment of patients with immunosuppressants, chemotherapy drugs, radiotherapy, or systemic corticosteroids; 2) Combined with a history of tumor and chemoradiotherapy (hematological malignancy, myelomatous nephropathy, hemolytic uremic syndrome, lymphoma, leukemia, immunoglobulin deposition nephropathy); 3) HIV patients with CD4 < 200/mm3; 4) History of obstructive diseases of the urinary system or conditions that may cause obstruction; 5) Glomerulonephritis, interstitial nephritis, renal amyloidosis, chronic renal failure with polycystic kidney, use of renal metabolized or nephrotoxic drugs 1 week before admission; 6) Rheumatic immune diseases (such as lupus); 7) Lack of follow-up data.

研究实施时间:

Study execute time:

From 2024-05-13 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-05-13 00:00:00 To 2024-08-25 00:00:00

干预措施:

Interventions:

组别:

糖尿病足溃疡组

样本量:

1000

Group:

diabetic foot ulcer group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

糖尿病非足部溃疡组

样本量:

1000

Group:

Diabetic non-foot ulcer group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

广州市 

Country:

China

Province:

Guangdong province

City:

Guangzhou city

单位(医院):

中山大学孙逸仙纪念医 

单位级别:

三甲 

Institution
hospital:

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

估算肾小球滤过率

指标类型:

主要指标

Outcome:

estimated glomerular filtration rate

Type:

Primary indicator

测量时间点:

患者入院时

测量方法:

血清肌酐是最常用的GFR估算标志物。 使用肌酐清除率(Ccr)或计算估计的GFR(eGFR)来评价肾功能。 CKD-EPI公式是一种常用的计算eGFR的方法。

Measure time point of outcome:

the time of patient admission.

Measure method:

Serum creatinine is the most commonly used marker for estimating glomerular filtration rate (GFR). Clinicians often assess renal function using either creatinine clearance (Ccr) or calculated estimated GFR (eGFR). The CKD-EPI formula is a commonly used method for calculating eGFR.

指标中文名:

尿蛋白排泄率

指标类型:

主要指标

Outcome:

urinary albumin excretion rate

Type:

Primary indicator

测量时间点:

患者入院时

测量方法:

尿蛋白排泄率测量,也称为24小时尿蛋白定量,包括收集24小时内的尿液以确定蛋白质含量。

Measure time point of outcome:

the time of patient admission.

Measure method:

Urinary protein excretion rate measurement, also known as 24-hour urinary protein quantification, involves collecting urine over a 24-hour period to determine the protein content.

指标中文名:

中性粒细胞

指标类型:

主要指标

Outcome:

neutrophil

Type:

Primary indicator

测量时间点:

患者入院时

测量方法:

电阻抗法

Measure time point of outcome:

the time of patient admission.

Measure method:

Coulter Principle

指标中文名:

糖尿病肾病患病率

指标类型:

主要指标

Outcome:

Prevalence of diabetic nephropathy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

全身免疫炎症指数

指标类型:

次要指标

Outcome:

systemic immune-inflammation index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

发表文章后

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After publishing the paper

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-09-03 15:25:15